Brazilian blood donation eligibility criteria for dermatologic patients.
A focused and commented review on the impact of dermatologic diseases and interventions in the solidary act of donating blood is presented to dermatologists to better advise their patients. This is a review of current Brazilian technical regulations on hemotherapeutic procedures as determined by Ministerial Directive #1353/2011 by the Ministry of Health and current internal regulations of the Hemotherapy Center of Ribeirão Preto, a regional reference center in hemotherapeutic procedures. Criteria for permanent inaptitude: autoimmune diseases (>1 organ involved), personal history of cancer other than basal cell carcinoma, severe atopic dermatitis or psoriasis, pemphigus foliaceus, porphyrias, filariasis, leprosy, extra pulmonary tuberculosis or paracoccidioidomycosis, and previous use of etretinate. Drugs that impose temporary ineligibility: other systemic retinoids, systemic corticosteroids, 5-alpha-reductase inhibitors, vaccines, methotrexate, beta-blockers, minoxidil, anti-epileptic, and anti-psychotic drugs. Other conditions that impose temporary ineligibility: occupational accident with biologic material, piercing, tattoo, sexually transmitted diseases, herpes, and bacterial infections, among others.


CONCLUSIONS
Thalidomide is currently missing in the teratogenic drugs list. Although finasteride was previously considered a drug that imposed permanent inaptitude, according to its short halflife current restriction of 1 month is still too long. Dermatologists should be able to advise their patients about proper timing to donate blood, and discuss the impact of drug withdrawal on treatment outcomes and to respect the designated washout periods.
Division of Dermatology, Internal Medicine Department, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil. cwambier@usp.br
Carlos Gustavo
CG
Wambier
Caroline Silva
CS
Pereira
Benedito de Pina Almeida
Bde P
Prado Júnior
Norma Tiraboschi
NT
Foss
D001782:Blood Donors / Q000331:legislation & jurisprudence*; D001938:Brazil; D003879:Dermatologic Agents / Q000009:adverse effects*; D046148:Donor Selection / Q000331:legislation & jurisprudence / Q000592:standards*; D006801:Humans; D012871:Skin Diseases / Q000150:complications* / Q000188:drug therapy
D003879:Dermatologic Agents